Bio/Pharma Business

Thermo Fisher Scientific Extends Collaboration Support for Biopharma Discovery and Development

March 03, 2022

Thermo Fisher and Symphogen have extended their collaboration involving improved data workflow, which supports the discovery and development of new cancer treatments.

IDT Biologika and Exothera Partner on Viral Vaccines Manufacturing

March 03, 2022

Under a collaboration, IDT Biologika and Exothera will conduct feasibility studies on scaling up the manufacturing process for viral vector-based vaccines.

Standing in Solidarity

March 02, 2022

As Russia’s invasion of Ukraine continues, industry leaders speak out in condemnation of the actions taking place and pledge to provide aid to those in need.

Biocon Biologics to Acquire Biosimilars Assets from Viatris in $3.3 Billion Deal

March 02, 2022

Biocon Biologics will acquire Viatris’ global biosimilars business, including the company’s portfolio of in-licensed biosimilar assets, in a transaction valued at over $3.3 billion.

UCB Announces Extension of Tender Offer to Acquire Zogenix

March 01, 2022

UCB has announced that it is extending its tender offer to acquire Zogenix.

Johnson & Johnson Confirm Advancement of Nationwide Opioid Settlement Agreement

February 28, 2022

Johnson & Johnson has confirmed advancement of the nationwide opioid settlement agreement.

Remix Therapeutics Collaborates with Janssen to Advance Small Molecule Therapeutics

February 24, 2022

Janssen will pay upwards of $1 billion for exclusive rights to use Remix’s RNA-based drug discovery platform on three specific targets.

Valneva Awarded R&D Funding by Scottish Enterprise for Vaccine Development

February 24, 2022

Scottish Enterprise has awarded £20 million (US$27 million) to Valneva Scotland to advance vaccine development.

Alvea to Develop New DNA Vaccine Against SARS-CoV-2 Variants

February 23, 2022

Alvea has begun preclinical testing of a scalable, shelf-stable DNA vaccine against SARS-CoV-2 variants.

Moderna and Thermo Fisher Scientific Form Long-Term Strategic Manufacturing Collaboration

February 23, 2022

Moderna and Thermo Fisher Scientific have formed a collaboration to leverage dedicated commercial fill/finish manufacturing capacity in the US for mRNA vaccines and therapies.